Novavax, Inc. (FRA:NVV1)

Novavax Statistics

Total Valuation

Novavax has a market cap or net worth of EUR 935.14 million. The enterprise value is 494.93 million.

Market Cap	935.14M
Enterprise Value	494.93M

Important Dates

The next estimated earnings date is Thursday, February 26, 2026.

Earnings Date	Feb 26, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	162.50M
Shares Outstanding	n/a
Shares Change (YoY)	+16.16%
Shares Change (QoQ)	-8.39%
Owned by Insiders (%)	0.51%
Owned by Institutions (%)	52.20%
Float	134.90M

Valuation Ratios

The trailing PE ratio is 3.21.

PE Ratio	3.21
Forward PE	n/a
PS Ratio	1.03
PB Ratio	-7.00
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 1.27, with an EV/FCF ratio of -1.51.

EV / Earnings	1.70
EV / Sales	0.54
EV / EBITDA	1.27
EV / EBIT	1.38
EV / FCF	-1.51

Financial Position

The company has a current ratio of 2.27

Current Ratio	2.27
Quick Ratio	1.85
Debt / Equity	n/a
Debt / EBITDA	0.56
Debt / FCF	-0.65
Interest Coverage	13.84

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	18.01%
Return on Invested Capital (ROIC)	n/a
Return on Capital Employed (ROCE)	55.57%
Revenue Per Employee	953,153
Profits Per Employee	305,955
Employee Count	952
Asset Turnover	0.74
Inventory Turnover	39.01

Taxes

In the past 12 months, Novavax has paid 7.62 million in taxes.

Income Tax	7.62M
Effective Tax Rate	2.55%

Stock Price Statistics

The stock price has decreased by -29.19% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-29.19%
50-Day Moving Average	6.94
200-Day Moving Average	6.59
Relative Strength Index (RSI)	45.76
Average Volume (20 Days)	2,950

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	11.50

Income Statement

In the last 12 months, Novavax had revenue of EUR 907.40 million and earned 291.27 million in profits. Earnings per share was 1.76.

Revenue	907.40M
Gross Profit	539.18M
Operating Income	355.26M
Pretax Income	298.89M
Net Income	291.27M
EBITDA	385.09M
EBIT	355.26M
Earnings Per Share (EPS)	1.76

Balance Sheet

The company has 650.21 million in cash and 214.05 million in debt, giving a net cash position of 436.17 million.

Cash & Cash Equivalents	650.21M
Total Debt	214.05M
Net Cash	436.17M
Net Cash Per Share	n/a
Equity (Book Value)	-133.53M
Book Value Per Share	-0.82
Working Capital	464.27M

Cash Flow

In the last 12 months, operating cash flow was -322.44 million and capital expenditures -4.62 million, giving a free cash flow of -327.06 million.

Operating Cash Flow	-322.44M
Capital Expenditures	-4.62M
Free Cash Flow	-327.06M
FCF Per Share	n/a

Margins

Gross margin is 59.42%, with operating and profit margins of 39.15% and 32.10%.

Gross Margin	59.42%
Operating Margin	39.15%
Pretax Margin	32.94%
Profit Margin	32.10%
EBITDA Margin	42.44%
EBIT Margin	39.15%
FCF Margin	n/a

Dividends & Yields

Novavax does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-16.16%
Shareholder Yield	-16.16%
Earnings Yield	31.15%
FCF Yield	-34.97%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on May 10, 2019. It was a reverse split with a ratio of 0.05.

Last Split Date	May 10, 2019
Split Type	Reverse
Split Ratio	0.05

Scores

Novavax has an Altman Z-Score of -2.23 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-2.23
Piotroski F-Score	5